Interaction of thymic peptide thymosin alpha 1 wit... - Thymosin-alpha-1 Study

Key Findings

Thymosin‑alpha‑1 (10⁻¹⁰‑10⁻⁷ M) modestly inhibits the binding of radiolabelled VIP.

It is roughly 1,500‑fold less potent than VIP at this inhibition.

It produces only weak stimulation of cyclic AMP production in rat intestinal cells.

Affinity ranking: VIP > PHI > secretin > thymosin‑alpha‑1.

Practical Outcomes

For biohackers, this means thymosin‑alpha‑1 is unlikely to provide meaningful effects on gut‑related VIP pathways, such as metabolism or motility, at typical doses. It does not suggest any new dosing strategy or health benefit, so it’s not a useful addition to longevity or performance protocols.

Summary

The study shows that thymosin‑alpha‑1 only barely interacts with the same gut receptors that the hormone VIP uses. It is far weaker—about 1,500 times less potent—at blocking VIP binding and only slightly raises cellular signaling (cAMP). In short, thymosin‑alpha‑1 isn’t a strong activator of these VIP receptors.

Abstract

1. Thymic peptide thymosin alpha 1 (10(-10)-10(-7) M) is shown to inhibit the specific binding of 125I-labelled VIP. 2. Thymosin alpha 1 was 1500 times less potent than VIP at inhibiting 125I-labelled VIP binding. 3. Thymosin alpha 1 (10(-10)-10(-7) M) was weak in stimulating cyclic AMP production. 4. Interaction of thymosin alpha 1 with VIP receptors is compared with PHI and secretin. 5. The order of affinity of different peptides is VIP greater than PHI greater than secretin greater than thymosin alpha 1.

Study Information

Provider

pubmed

Year

1989

DOI

10.1016/0306-3623(89)90203-6

Citations

References